Fellowship · Brooklyn, NY
Sponsored by Maimonides Medical Center
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
The Lancet. Oncology · 2021 · 557 citations · Mohammad Razaq
Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.
Cancers · 2023 · 153 citations · Yiquing Xu
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.
Head & neck · 2021 · 152 citations · Mohammad Razaq
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 172 citations · Oscar Lahoud
A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model.
Cancer discovery · 2026 · 13 citations · Oscar Lahoud
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood · 2024 · 54 citations ·
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.
The Lancet. Oncology · 2023 · 71 citations · Oscar Lahoud
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood advances · 2024 · 50 citations · Oscar Lahoud